这是一篇来自已证抗体库的有关
人类 MSH6的综述，是根据24篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合MSH6 抗体。
MSH6 同义词: GTBP; GTMBP; HNPCC5; HSAP; p160
艾博抗（上海）贸易有限公司
| domestic rabbit 单克隆（EPR3945） | | 艾博抗（上海）贸易有限公司 MSH6抗体（AbCam, Ab92471)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 4b). Nat Commun (2021) ncbi |
| domestic rabbit 单克隆（EPR3945） | | 艾博抗（上海）贸易有限公司 MSH6抗体（Abcam, ab92471)被用于被用于免疫印迹在人类样本上 (图 s1). Aging (Albany NY) (2021) ncbi |
| domestic rabbit 单克隆（EPR3945） | | 艾博抗（上海）贸易有限公司 MSH6抗体（Abcam, ab92471)被用于被用于免疫组化在小鼠样本上浓度为1:500 (图 s2a). JCI Insight (2020) ncbi |
| domestic rabbit 单克隆（EPR3945） | | 艾博抗（上海）贸易有限公司 MSH6抗体（Abcam, ab92471)被用于被用于免疫印迹在人类样本上 (图 e8k). Nature (2019) ncbi |
赛默飞世尔
| 小鼠 单克隆（44） | | 赛默飞世尔 MSH6抗体（Zymed, 08-1374)被用于被用于免疫组化-石蜡切片在人类样本上. BMC Surg (2014) ncbi |
| 小鼠 单克隆（44） | | 赛默飞世尔 MSH6抗体（Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Hum Pathol (2011) ncbi |
| 小鼠 单克隆（44） | | 赛默飞世尔 MSH6抗体（Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Fam Cancer (2010) ncbi |
| 小鼠 单克隆（44） | | 赛默飞世尔 MSH6抗体（Zymed, 44)被用于被用于免疫组化-石蜡切片在人类样本上. Gynecol Oncol (2009) ncbi |
| 小鼠 单克隆（44） | | 赛默飞世尔 MSH6抗体（Zymed Laboratories, 44)被用于被用于免疫组化-石蜡切片在人类样本上. APMIS (2008) ncbi |
丹科医疗器械技术服务（上海）有限公司
| domestic rabbit 单克隆（EP49） | | 丹科医疗器械技术服务（上海）有限公司 MSH6抗体（Dako, IR086)被用于被用于免疫组化-石蜡切片在人类样本上 (图 1). Cancer Manag Res (2020) ncbi |
| domestic rabbit 单克隆（EP49） | | 丹科医疗器械技术服务（上海）有限公司 MSH6抗体（Dako, EP49)被用于被用于免疫组化在人类样本上浓度为1:1000 (图 1f). PLoS ONE (2020) ncbi |
| domestic rabbit 单克隆（EP49） | - 免疫组化-石蜡切片; 人类; 1:100; 表 1
| 丹科医疗器械技术服务（上海）有限公司 MSH6抗体（Dako, M3646)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 1). Br J Cancer (2016) ncbi |
赛信通（上海）生物试剂有限公司
| domestic rabbit 单克隆（D60G2） | - 免疫印迹基因敲除验证; 人类; 1:1000; 图 s1b
- 免疫印迹; 人类; 1:1000; 图 s1b
| 赛信通（上海）生物试剂有限公司 MSH6抗体（Cell Signaling, D60G2)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 s1b) 和 被用于免疫印迹在人类样本上浓度为1:1000 (图 s1b). Nat Commun (2018) ncbi |
| domestic rabbit 单克隆（D60G2） | | 赛信通（上海）生物试剂有限公司 MSH6抗体（Cell Signaling, 5424)被用于被用于免疫印迹在人类样本上 (图 s1). Proc Natl Acad Sci U S A (2016) ncbi |
碧迪BD
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD, 610918)被用于被用于免疫印迹在人类样本上 (图 1s1c). elife (2019) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Transduction Laboratories, 44/MSH6)被用于被用于免疫组化-石蜡切片在人类样本上 (表 2). Am J Surg (2017) ncbi |
| 小鼠 单克隆（44/MSH6） | - 免疫印迹基因敲除验证; 小鼠; 1:1000; 图 4
| 碧迪BD MSH6抗体（BD Biosciences, 610918)被用于被用于免疫印迹基因敲除验证在小鼠样本上浓度为1:1000 (图 4). PLoS Genet (2016) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Biosciences, 610919)被用于被用于免疫组化在人类样本上浓度为1:800 (图 s4b). Nat Med (2016) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Pharmingen, 44)被用于被用于免疫组化在人类样本上浓度为1:100. JAMA Oncol (2016) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Biosciences, 610918)被用于被用于免疫印迹在小鼠样本上浓度为1:2500 (图 4a). DNA Repair (Amst) (2016) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Transduction Laboratories, 44/MSH6)被用于被用于免疫组化在人类样本上浓度为1:200. Virchows Arch (2015) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Pharmingen, 610919)被用于被用于免疫组化-石蜡切片在人类样本上. Cancer Genet (2014) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Biosciences, 44/MSH6)被用于被用于免疫组化在人类样本上浓度为1:100 (图 1). Cancer Genet (2013) ncbi |
| 小鼠 单克隆（44/MSH6） | | 碧迪BD MSH6抗体（BD Bioscience, 610919)被用于被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. PLoS ONE (2013) ncbi |
Laliotis G, Chavdoula E, Paraskevopoulou M, Kaba A, La Ferlita A, Singh S,
et al. AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing. Nat Commun. 2021;12:4624
pubmed 出版商 Zhou Z, Tan F, Pei Q, Li C, Zhou Y, Li Y,
et al. lncRNA SNHG4 modulates colorectal cancer cell cycle and cell proliferation through regulating miR-590-3p/CDK1 axis. Aging (Albany NY). 2021;13:9838-9858
pubmed 出版商 Li H, Lu C, Zhang H, Hu Q, Zhang J, Cuevas I,
et al. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight. 2020;5:
pubmed 出版商 Shao W, Wang C, Wang L, Xiao F, Xiao D, Yang H,
et al. A Hereditable Mutation of MSH2 Gene Associated with Lynch Syndrome in a Five Generation Chinese Family. Cancer Manag Res. 2020;12:1469-1482
pubmed 出版商 Rübben A, Wahl R, Eggermann T, Dahl E, Ortiz Brüchle N, Cacchi C. Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype. PLoS ONE. 2020;15:e0230003
pubmed 出版商 Pech M, Fong L, Villalta J, Chan L, Kharbanda S, O Brien J,
et al. Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. elife. 2019;8:
pubmed 出版商 Wang J, Liu Y, Liu Y, Zheng S, Wang X, Zhao J,
et al. Time-resolved protein activation by proximal decaging in living systems. Nature. 2019;569:509-513
pubmed 出版商 Zou X, Owusu M, Harris R, Jackson S, Loizou J, Nik Zainal S. Validating the concept of mutational signatures with isogenic cell models. Nat Commun. 2018;9:1744
pubmed 出版商 Massalou D, Benizri E, Chevallier A, Duranton Tanneur V, Pedeutour F, Benchimol D,
et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377-387
pubmed 出版商 Zhao X, Lokanga R, Allette K, Gazy I, Wu D, Usdin K. A MutS?-Dependent Contribution of MutS? to Repeat Expansions in Fragile X Premutation Mice?. PLoS Genet. 2016;12:e1006190
pubmed 出版商 Hrecka K, Hao C, Shun M, Kaur S, Swanson S, Florens L,
et al. HIV-1 and HIV-2 exhibit divergent interactions with HLTF and UNG2 DNA repair proteins. Proc Natl Acad Sci U S A. 2016;113:E3921-30
pubmed 出版商 Park J, Powell A, Roxburgh C, Horgan P, McMillan D, Edwards J. Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment. Br J Cancer. 2016;114:562-70
pubmed 出版商 Beltran H, Prandi D, Mosquera J, Benelli M, Puca L, Cyrta J,
et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298-305
pubmed 出版商 Taieb J, Zaanan A, Le Malicot K, Julie C, Blons H, Mineur L,
et al. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. JAMA Oncol. 2016;2:643-653
pubmed 出版商 Fischer J, Dudley S, Miller A, Liskay R. An intact Pms2 ATPase domain is not essential for male fertility. DNA Repair (Amst). 2016;39:46-51
pubmed 出版商 Vanoli A, Argenti F, Vinci A, La Rosa S, Viglio A, Riboni R,
et al. Hepatoid carcinoma of the pancreas with lymphoid stroma: first description of the clinical, morphological, immunohistochemical, and molecular characteristics of an unusual pancreatic carcinoma. Virchows Arch. 2015;467:237-45
pubmed 出版商 Vilar E, Mork M, Cuddy A, Borràs E, Bannon S, Taggart M,
et al. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet. 2014;207:495-502
pubmed 出版商 Baiocchi G, Portolani N, Vermi W, Baronchelli C, Gheza F, Zogno C,
et al. Lynch syndrome from a surgeon perspective: retrospective study of clinical impact of mismatch repair protein expression analysis in colorectal cancer patients less than 50 years old. BMC Surg. 2014;14:9
pubmed 出版商 Dadone B, Ambrosetti D, Carpentier X, Duranton Tanneur V, Burel Vandenbos F, Amiel J,
et al. A renal metanephric adenoma showing both a 2p16e24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?. Cancer Genet. 2013;206:347-52
pubmed Gupte M, Tuck A, Sharma V, Williams K. Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator. PLoS ONE. 2013;8:e74071
pubmed 出版商 Gatalica Z, Lilleberg S, Monzon F, Koul M, Bridge J, Knezetic J,
et al. Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes. Hum Pathol. 2011;42:1979-88
pubmed 出版商 Cossio S, Koehler Santos P, Pessini S, Mónego H, Edelweiss M, Meurer L,
et al. Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil. Fam Cancer. 2010;9:131-9
pubmed 出版商 Arabi H, Guan H, Kumar S, Cote M, Bandyopadhyay S, Bryant C,
et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol. 2009;113:153-8
pubmed 出版商 Mylona E, Zarogiannos A, Nomikos A, Giannopoulou I, Nikolaou I, Zervas A,
et al. Prognostic value of microsatellite instability determined by immunohistochemical staining of hMSH2 and hMSH6 in urothelial carcinoma of the bladder. APMIS. 2008;116:59-65
pubmed 出版商
